Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

114 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma.
Aparicio J, García del Muro X, Maroto P, Paz-Ares L, Alba E, Sáenz A, Terrasa J, Barnadas A, Almenar D, Arranz JA, Sánchez M, Fernández A, Sastre J, Carles J, Dorca J, Gumà J, Yuste AL, Germà JR; Spanish Germ Cell Cancer Cooperative Group (GG). Aparicio J, et al. Among authors: maroto p. Ann Oncol. 2003 Jun;14(6):867-72. doi: 10.1093/annonc/mdg241. Ann Oncol. 2003. PMID: 12796024 Free article.
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Roldán-Romero JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez-Montes A, Monteagudo M, Mellid S, Leandro-García LJ, Montero-Conde C, Cascón A, Roncador G, Coloma J, Robledo M, Rodriguez-Antona C. Roldán-Romero JM, et al. Among authors: maroto p. Int J Cancer. 2023 Sep 15;153(6):1300-1312. doi: 10.1002/ijc.34575. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260183
Recommendations on the treatment of metastatic hormone-sensitive prostate cancer: Patient selection.
Borque-Fernando Á, Zapatero A, Manneh R, Alonso-Gordoa T, Couñago F, Domínguez-Esteban M, López-Valcárcel M, Rodríguez-Antolín A, Sala-González N, Sanmamed N, Maroto P; en representación del Grupo Guard de Investigación Multidisciplinar en Tumores genitourinarios. Borque-Fernando Á, et al. Among authors: maroto p. Actas Urol Esp (Engl Ed). 2024 Nov;48(9):623-631. doi: 10.1016/j.acuroe.2024.05.008. Epub 2024 May 11. Actas Urol Esp (Engl Ed). 2024. PMID: 38740263 Free article. English, Spanish.
Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.
Climent MÁ, Álvarez C, Morales R, Maroto P, Rodríguez-Vida A, Méndez-Vidal MJ, Del Muro XG, Puente J, Láinez N, Vázquez S, Castellano D, Lang CG, Wang J, di Pietro A, Davis C, Sanz-Castillo B, Bolós MV, Valderrama BP. Climent MÁ, et al. Among authors: maroto p. Clin Transl Oncol. 2024 Jun;26(6):1532-1538. doi: 10.1007/s12094-023-03358-4. Epub 2023 Dec 15. Clin Transl Oncol. 2024. PMID: 38102374 Free PMC article. Clinical Trial.
Challenges of diagnosing homologous recombination deficiencies in metastatic prostate cancer: a six-year experience from a single institution.
Gavira J, Tapia JC, Romano A, Anguera G, Aguado M, Piedra A, Bosma F, Sánchez S, Martin C, Algaba F, Arce Y, Ramón Y Cajal T, Maroto P. Gavira J, et al. Among authors: maroto p. Clin Transl Oncol. 2024 Oct;26(10):2749-2753. doi: 10.1007/s12094-024-03483-8. Epub 2024 May 9. Clin Transl Oncol. 2024. PMID: 38722534
[Practical aspects of PD-L1 assessment in the treatment of urothelial carcinoma: Consensus of the uropathology group of the SEAP].
López-Beltrán A, González-Peramato P, Sanz-Ortega J, Prieto Cuadra JD, Trias I, Luque Barona RJ, Semidey ME, Maroto P, Algaba F. López-Beltrán A, et al. Among authors: maroto p. Rev Esp Patol. 2023 Oct-Dec;56(4):261-270. doi: 10.1016/j.patol.2023.05.001. Epub 2023 Sep 1. Rev Esp Patol. 2023. PMID: 37879823 Review. Spanish.
114 results